ORIGINAL ARTICLE
Local inflammatory response in colorectal cancer
Submission date: 2015-11-22
Final revision date: 2016-03-14
Acceptance date: 2016-03-22
Publication date: 2016-08-02
Pol J Pathol 2016;67(2):163-171
KEYWORDS
TOPICS
ABSTRACT
Type and intensity of tumor-infiltrating lymphocytes (TILs) in close proximity to the primary tumor are prognostically significant in postoperative patients. High intensity of TILs is considered to be a prognostically beneficial factor. The research included 66 postoperative colorectal cancer patients. The control group comprised 20 colon segments. Monoclonal antibodies LCA, CD3, CD4, CD5, CD8, CD20, CD23 and CD138 were used to differentiate between T and B lymphocytes. Types of cells in the infiltrate were defined. We found greater numbers of T and B lymphocytes located in close proximity to the cancerous tissue when compared to the control group. T lymphocyte intensity in the inflammatory infiltrations was directly correlated with the size of resected tumors, presence of regional lymphatic node metastases and histological grade of malignancy. Lymphocytic infiltrations of greater intensity located in close proximity to the primary tumor were found in subjects with less advanced colorectal cancer.
The research presented here proves direct dependence between the immune system and colorectal cancer. The presence of lymphocytes in the inflammatory infiltrations located in close proximity to the cancerous tissue has been proved to be prognostically beneficial. The obtained results support the application of immunotherapy in colorectal cancer treatment.
The research presented here proves direct dependence between the immune system and colorectal cancer. The presence of lymphocytes in the inflammatory infiltrations located in close proximity to the cancerous tissue has been proved to be prognostically beneficial. The obtained results support the application of immunotherapy in colorectal cancer treatment.
REFERENCES (26)
1.
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130.
2.
Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38: 451-466.
3.
Richards CH, Roxburgh CS, Powell AG, et al. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014; 50: 309-319.
4.
Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-1813.
5.
Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, et al. Tumor infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48: 360-366.
6.
Koch M, Beckhove P, op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer. Tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006; 244: 986-992.
7.
Lemancewicz D, Bolkun L, Jablonska E, et al. Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features. Leukemia Research 2013; 37: 1089-1093.
8.
Funada Y, Noguchi T, Kikuchi R, et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10: 309-313.
9.
Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
11.
McMillan DC, Fyffe GD, Wotherspoon HA, et al. Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer. Dis Colon Rectum 1997; 40: 1068-1071.
12.
Ordemann J, Jacobi CA, Braumann C, et al. Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis 2002; 17: 37-41.
13.
Nascimbeni R, Di Fabio F, Di Betta E, et al. Morphology of colorectal lymphoid aggregates in cancer, diverticular and inflammatory bowel diseases. Mod Pathol 2005; 18: 681-685.
14.
Maxwell-Armstrong CA, Durrant LG, Robins RA, et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999; 45: 593-598.
15.
Buckley DT, Robins AR, Durrant LG. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas 1995; 6: 68-72.
16.
Habal N, Gupta RK, Bilchik AJ, et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001; 8: 389-401.
17.
Klintrup K, Mäkinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-2654.
18.
Di Giorgio A, Botti C, Tocchi A, et al. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg 1992; 77: 256-260.
19.
Lackner C, Jukic Z, Tsybrovskyy O, et al. Prognostic relevance of tumor-associated macrophages and von Willebrand factor positive microvessels in colorectal cancer. Virchows Arch 2004; 445: 160-167.
20.
Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182: 318-324.
21.
George S, Primrose J, Talbot R, et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006; 95: 841-847.
22.
Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
23.
Nagtegaal ID, Marijnen CA, Kranenberg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect – a histopathological and immunohistochemical study. BMC Cancer 2001; 1: 7.
24.
Dillman R, Schiltz P, DePriest C, et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004; 19: 730-737.
25.
Lemancewicz D, Bolkun L, Porowska H, et al. The levels of sMUC-1 in patients with multiple myeloma. Folia Histochem Cytobiol 2011; 49: 654-658.
26.
Li Z, Liu X, Wan Y, et al. Antitumor effect of an antibody against gastrointestinal cancer-associated antigen CA19.9. Cancer Biother Radiopharm 2007; 22: 597-606.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
